Oura, the prominent maker of health-tracking smart rings, has officially postponed its planned initial public offering on the Nasdaq exchange. The San Francisco-based company cited broad market uncertainty as the primary reason for holding back, despite reporting strong underlying business metrics and solid investor interest.
The company formally launched its IPO campaign on September 21, aiming to raise up to $2.2 billion through the sale of 50 million shares. The proposed share price range was set between $40 and $44 apiece, which would have valued the consumer technology firm at approximately $15.62 billion on a fully diluted basis.
Despite strong engagement from institutional buyers and strategic partners-such as potential share acquisitions from Eli Lilly and investment firm Dragoneer-leadership decided to step back as macroeconomic headwinds began to mount across the wider stock market.
Weighing Market Volatility and IPO Timing
Oura CEO Tom Hale addressed the postponement in a formal statement. He emphasized the firm’s solid financial foundation and patience regarding public market entry.
“We aim to deliver an extraordinary IPO for our employees and investors and we have the luxury of choosing our moment. In the meantime, we will execute against the opportunities ahead,” Hale said.
The delay reflects a sluggish fall IPO environment. Wall Street investors have grown increasingly cautious. Concerns include lingering Federal Reserve monetary policy adjustments, rising bond yields, ongoing geopolitical turmoil, and sharp valuation swings in artificial intelligence stocks. Oura’s decision mirrors similar moves by other major entities, such as Holtec Nuclear and Bamboo Insurance, which also recently suspended or delayed their public offerings due to unfavorable market conditions.
Strong Financial Performance and Business Growth
While macro conditions triggered the postponement, Oura’s internal business metrics remain robust. The company reported that its financial standing has continued to strengthen since initiating the IPO roadmap:
- Revenue Growth: Revenue for the nine months ended June 30 reached $1.21 billion, marking an approximate 75% to 90% year-over-year expansion path heading into fiscal 2026.
- Subscriber Base: Paid active members on the platform have climbed to 5.7 million users, supported by an impressive 85% subscription renewal rate.
- Profitability: Unlike many pre-IPO tech startups, Oura confirmed it is profitable, reporting notable pretax earnings alongside strong device adoption rates.
The company’s flagship smart rings track core health indicators. These include sleep quality, physical activity, heart health, and women’s health metrics, feeding continuous data into a dedicated companion mobile application. Private funding rounds previously valued the company at roughly $11 billion following a massive $900 million Series E round last October.
Underwriting and Next Steps
The planned offering was backed by an elite roster of financial institutions. Goldman Sachs, Morgan Stanley, and J.P. Morgan served as lead underwriters for the transaction. Allen & Company and Jefferies acted as joint lead book-running managers.
Of the 50 million shares originally lined up for sale, Oura planned to offer 13.5 million shares. Existing stockholders were set to sell the remaining 36.5 million. Underwriters were also granted a 30-day option to acquire up to 7.5 million additional shares from selling stakeholders.
Oura has not yet announced a revised timeline or a future target date for returning to the Nasdaq IPO queue. Management will continue focusing on core product execution and expanding its global subscriber ecosystem until market conditions stabilize.
